Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses

Montefiore Medical Center · with National Institute on Drug Abuse (NIDA), New York University · NCT07631598

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18+ · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Not applicable
Target enrollment
512
US sites recruiting
8
Study start
August 17, 2026
Record last updated
October 1, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

This study is testing whether offering buprenorphine treatment directly at syringe service programs (SSPs) helps more people start and stay in treatment for opioid use disorder (OUD) than referring them to community buprenorphine treatment providers. Buprenorphine is a medication that helps reduce opioid cravings and withdrawal symptoms.

The study compares two ways of connecting people to treatment:

Referral to a community treatment provider (usual care before the new program begins).

Onsite, low-threshold buprenorphine treatment at the SSP, which allows participants to start medication quickly and without having to establish care at another provider.

Participants will be adults who have opioid use disorder and are SSP clients. Each SSP will begin offering the new onsite buprenorphine program at different times during the study. Researchers will collect information before and after the new program begins to see how it affects treatment engagement and health outcomes.

The study will also examine how easy or difficult it is for SSPs to start and run the new program, how acceptable it is to staff and participants, and whether it is cost-effective.

The overall goal is to find better ways to expand access to life-saving opioid treatment in community-based settings.

Being studied: Standard of Care Referral; Low Threshold Buprenorphine

Conditions: Opioid Use Disorder; Opioid Use Disorder, Severe; Opioid Use Disorder, Moderate

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • ≥ 18 years old;
  • Meet DSM-5 criteria for moderate or severe OUD;
  • Interest in receiving buprenorphine treatment;
  • Speaks English or Spanish;
  • Currently an SSP client at the time of enrollment;
  • Ability to provide informed consent.

Exclusion Criteria

  • Current use of prescribed opioid agonist treatment, as assessed by self-report, at the time of enrollment;
  • Unstable mental health or medical condition that requires an immediate clinical evaluation or higher level of care;
  • Allergy to buprenorphine;
  • Currently detained in jail, prison, residential substance use treatment facility, or other overnight facility as required by court of law. or have pending legal action that could prevent participation on study activities.

Recruiting US locations

  • Community Health Project Los Angeles (CHPLA)

    Los Angeles, CA 90029

    Site contact: Site PI · 323-380-5469 · info@chpla.org

  • HIPS

    Washington D.C., DC 20002

    Site contact: Phyllis Bijole · 202-834-3289 · phyllis@hips.org

  • CARPBR/Be Safe Syringe Program

    Baton Rouge, LA 70806

    Site contact: Site PI · 225-775-7988 · gjvar.carpbr@gmail.com

  • Harm Reduction Sisters

    Duluth, MN 55805

    Site contact: Jack Research Coordinator · 218-206-6482 · jack@harmreductionsisters.org

  • Alianza of New Mexico

    Roswell, NM 88203

    Site contact: Ryan Nix Site PI · 575-623-1995 · ryan.nix@alianzanm.org

  • HIV Alliance

    Grants Pass, OR 97526

    Site contact: Harmony Beckett · 541-342-5088 · hbeckett@allianceor.org

  • Challenges, Inc/Prisma Health

    Greenville, SC 29605

    Site contact: Liam Diaz, MPH · 864-915-2528 · Liam.Diaz@prismahealth.org

  • Vivent Health

    Milwaukee, WI 53212

    Site contact: Site PI · 800-359-9272 · ctgov.research@viventhealth.org

Study contacts (from the official record)

  • Megan M Ghiroli · 12036068136 · mghiroli@montefiore.org
  • Aaron D Fox, MD, MS · adfox@montefiore.org
All healthy volunteers studies in California →
Buprenorphine Implementation at Syringe Service Programs to Reduce… (NCT07631598) | Bored Studies